Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma
- 6 January 2020
- journal article
- editorial
- Published by Elsevier BV in Annals of Oncology
- Vol. 31 (2), 169-170
- https://doi.org/10.1016/j.annonc.2019.12.004
Abstract
No abstract availableFunding Information
- Cancer Research UK
- National Institute for Health Research
- Rosetrees Trust
This publication has 16 references indexed in Scilit:
- Molecular mechanisms of therapy resistance in solid tumors: chasing “moving” targetsVirchows Archiv A Pathological Anatomy and Histopathology, 2017
- Cell population heterogeneity and evolution towards drug resistance in cancer: Biological and mathematical assessment, theoretical treatment optimisationBiochimica et Biophysica Acta (BBA) - General Subjects, 2016
- N-Myc Drives Neuroendocrine Prostate Cancer Initiated from Human Prostate Epithelial CellsCancer Cell, 2016
- Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibitionNature Medicine, 2016
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Transformation from NSCLC to SCLC: when did it happen?The Lancet Oncology, 2015
- Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originThe Lancet Oncology, 2015
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancerNature Communications, 2015
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-SmokersCell, 2012
- Nonsmall cell lung cancer in never smokersCurrent Opinion in Oncology, 2009